伦瓦提尼
医学
彭布罗利珠单抗
肾细胞癌
内科学
肿瘤科
免疫疗法
卡波扎尼布
肾癌
肾透明细胞癌
酪氨酸激酶抑制剂
临床试验
索拉非尼
癌症
肝细胞癌
作者
Toni K. Choueiri,Thomas Powles,Martin H. Voss,Elizabeth R. Plimack,Howard Gurney,Yue Song,Rodolfo F. Perini,Karla Rodriguez-Lopez,Brian I. Rini
出处
期刊:Future Oncology
[Future Medicine]
日期:2023-10-26
卷期号:19 (40): 2631-2640
被引量:2
标识
DOI:10.2217/fon-2023-0283
摘要
Combination treatment with immunotherapy agents and/or vascular endothelial growth factor tyrosine kinase inhibitors are a standard of care for patients with advanced clear cell renal cell carcinoma (ccRCC). Novel therapeutic combinations that include the hypoxia-inducible factor 2α inhibitor belzutifan and the cytotoxic T-lymphocyte–associated protein 4 inhibitor quavonlimab are being investigated for their potential to further improve patient outcomes. This protocol describes the rationale and design of the randomized, phase III LITESPARK-012 study, which will evaluate the efficacy and safety of pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab as first-line treatment for advanced ccRCC. Results from this study may support triplet combination therapies as a potential new standard of care for advanced ccRCC. Clinical trial registry: NCT04736706 (ClinicalTrials.gov)
科研通智能强力驱动
Strongly Powered by AbleSci AI